SCHEMBL31516751

SCHEMBL31516751

COc1ccc(S(=N)(=O)NC(=O)c2ccc(Cn3cccn3)c(OC)n2)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KAT7 O95251 9/20 0.46
▸ KAT6A Q92794 9/20 0.46
▸ KAT6B Q8WYB5 4/20 0.46
▸ KAT5 Q92993 3/20 0.46
▸ KAT8 Q9H7Z6 3/20 0.46
▸ LMNA P02545 2/20 0.42
▸ MAPT P10636 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ USP2 O75604 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ RAPGEF3 O95398 1/20 0.38
▸ TAS1R3 Q7RTX0 1/20 0.38
▸ TAS1R1 Q7RTX1 1/20 0.38
▸ ALPL P05186 1/20 0.37
▸ NAMPT P43490 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31516666 0.93 KAT7 (0.49) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516768 0.91 KAT7 (0.42) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516660 0.91 KAT7 (0.42) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516664 0.91 KAT7 (0.42) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516656 0.90 KAT7 (0.44) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31172765 0.86 KAT7 (0.44) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516667 0.86 KAT6A (0.40) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516691 0.86 KAT6A (0.40) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31516737 0.86 KAT7 (0.37) KAT7KAT6AKAT6BKAT5KAT8
SCHEMBL31172523 0.86 KAT7 (0.47) KAT7KAT6AKAT6BKAT5KAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KAT7 5/4885KAT6A 1/4885KAT6B 3/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B KAT7 5/4885KAT6A 1/4885KAT6B 3/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KAT7 4/4885KAT6A 1/4885KAT6B 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback